Berlin

• Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f … Ended recruitment
  2024-515224-37-00 4 2023-08-29 Patients with MSI-high or MMR-deficient stage III colorectal cancer wh
• The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early … Ended recruitment
  2024-512980-29-00 4 2023-08-28 T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-20 … Ended recruitment
  2022-500758-41-00 1 2023-08-15 Amyotrophic lateral sclerosis
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants wit … Ended recruitment
  2022-500221-33-01 5 2023-07-28 Hemophilia
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended recruitment
  2024-515027-11-00 4 2023-06-29 Crohn’s disease
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended recruitment
  2022-502145-10-00 5 2023-06-06 Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Ended recruitment
  2022-500929-33-01 10 2023-05-17 Human Immunodeficiency Virus (HIV-1) infection
• Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended recruitment
  2023-508499-12-00 5 2023-05-17 Systemic Lupus Erythematosus
• A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended recruitment
  2022-502634-52-00 5 2023-05-16 prostate cancer
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4) Ended recruitment
  2022-502215-10-00 5 2023-05-04 Haemophilia A (with or without inhibitors)
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended recruitment
  2022-501463-40-01 5 2023-05-03 Locally Advanced or Metastatic Cholangiocarcinoma
• A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended recruitment
  2023-508462-15-00 10 2023-04-27 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended recruitment
  2024-510742-13-00 5 2023-04-19 Pediatric low-grade glioma harboring an activating RAF alteration requ
• An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended recruitment
  2022-501480-41-00 5 2023-04-06 Psoriatic Arthritis
• A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex … Ended recruitment
  2024-513462-19-00 5 2023-03-30 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Ended recruitment
  2024-511370-72-00 4 2023-03-29 Primary Sclerosing Cholangitis

Showing 1,057–1,080 of 1,776 trials